Variational autoencoders (VAEs) are deep latent space generative models that have been
immensely successful in multiple exciting applications in biomedical informatics such as …

Diabetic kidney disease (DKD) is not only one of the main complications of diabetes, but
also the leading cause of the end-stage renal disease (ESRD). The occurrence and …

Background: Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high
mortality and morbidity. We aimed to determine the relative benefits of pharmacological …

Abstract Background and Purpose: Delayed cerebral ischemia is a major cause of morbidity
and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH). Cilostazol, a …

Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with
a low rate of bleeding complications. It has been used over the past 25 years for improving …

Background Type 2 diabetes mellitus is a risk factor for lower extremity arterial disease.
Cilostazol expresses antiplatelet, anti‐inflammatory, and vasodilator actions and improves …

Raynaud's Phenomenon (RP) results from exaggerated cold-induced vasoconstriction. RP
patients suffer from vasospastic attacks and compromised digital blood perfusion leading to …

Lorlatinib is a pharmaceutical ALK kinase inhibitor used to treat ALK driven non-small cell
lung cancers. This paper analyses the intersection of past published data on the …

Purpose: The purpose of this study is to assess the efficacy and safety of cilostazol
prescription in patients with femoropopliteal peripheral artery disease (PAD) after …

Methods A randomized, open-label, multiple-dosing, two-arm, two-period study was
conducted. Arm A had 30 participants receiving 200 mg cilostazol daily and arm B had 27 …